Breaking Ground: The Combine Group’s Latest Venture in Novel Immunotherapies for Tuberculosis and Mycobacterial Diseases

The Combine Group is delighted to announce our involvement in yet another project funded under the Horizon Europe Program:

Novel Immunotherapies for Tuberculosis and other Mycobacterial Diseases (ITHEMYC)

???? This venture is a significant opportunity to apply innovative solutions in silico modelling to facilitate both in vitro and in vivo preclinical progression and predict the therapeutic efficacy in the clinical stages of Tuberculosis.

???? Stay updated on the latest developments of this cutting-edge project by following us on social media:

LinkedIn: https://lnkd.in/eua57aRt
Twitter: https://lnkd.in/eKDZp-vw